<DOC>
	<DOCNO>NCT00725920</DOCNO>
	<brief_summary>The study 12-week randomize placebo control trial compare topiramate treat patient posttraumatic stress disorder , accord DSM-IV criterion . Patients receive topiramate placebo , dose start 25 mg/day every week 25mg increment accord patient tolerance side effect . Patients evaluate blind raters use Clinician-Administered PTSD Scale ( CAPS ) , Beck Depression Inventory ( BDI ) , Beck Anxiety Inventory ( BAI ) , 36-Item Short Form Health Survey ( SF-36 ) , Social Adjustment Scale ( SAS ) . outcome improvement Posttraumatic Stress Disorder ( PTSD ) , Depression , Anxiety , quality life social adjustment scale accord scale .</brief_summary>
	<brief_title>Placebo Controled Clinical Trial Using Topiramate To Treat Posttraumatic Stress Disorder ( PTSD ) Patients .</brief_title>
	<detailed_description>Seventy-two ( 72 ) patient randomly allocate , stratified manner , accord sex comorbidity depression , two ( 2 ) group : topiramate routine clinical follow-up , group would receive placebo pill routine clinical follow-up . The patient submit evaluation train independent researcher , apply structured clinical interview DSM-IV order evaluate presence psychiatric disorder ( SCID I SCID-II ) ; scale evaluation Impact Event Scale-IES ; frequency intensity symptom PTSD variation associate trauma ( PTSD Scale administer clinical personnel : `` Clinician-Administered PTSD Scale '' - CAPS ) ; severity depression : Beck Depression Inventory ( BDI ) anxiety : Beck Anxiety Inventory ( BAI ) ; scale evaluation social adaptation : Social Adjustment Scale ( SAS ) ; scale evaluation Quality Life : 36-Item Short Form Health Survey ( SF-36 ) ; scale evaluation global functioning axis V DSM-IV ( AGF ) . The patient receive active treatment twelve ( 12 ) week . After period , patient use topiramate improvement clinical condition continue receive treatment another twelve ( 12 ) week . Patients medication suspend twenty four ( 24 ) week followed-up twenty four ( 24 ) week . Patients placebo group show improvement continue receive clinical follow-up thirty six ( 36 ) week . Patients placebo group show worsen clinical status , evaluate CGI , exclude study send traditional treatment PROVE ( Violence Stress Program ) clinic . Patients terminate active phase study obtain clinical improvement send traditional treatment PROVE clinic . The principal outcome examine : Response ( decrease 50 % CAPS score start baseline ) remission ( lack diagnostic criterion PTSD CAPS ) . After end treatment , collect data tabulate compare use parametric non-parametric test . In study validation CAPS scale Portuguese carry .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Stress Disorders , Traumatic</mesh_term>
	<mesh_term>Stress Disorders , Post-Traumatic</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<criteria>Outpatient , male female 18 60 yr old PTSD diagnostic accord DSMIV criterion Patients agree receive diagnostic SCID I application trained psychiatrist Sexually active female patient agree use contraceptive Patients agree sign IRB approve informed consent Patients schizophrenic disorder , delusional , psychotic depression , schizoaffective , bipolar dependence psychoactive substance disorder Patients clinical disorder compensate , require clinical treatment priority Pregnancy Previous renal calculosis history Being antidepressant , psychotropic medication BMI 20 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>PTSD ,</keyword>
	<keyword>posttraumatic</keyword>
	<keyword>stress</keyword>
	<keyword>disorder ,</keyword>
	<keyword>randomization ,</keyword>
	<keyword>placebo ,</keyword>
	<keyword>control</keyword>
</DOC>